EUCTR2004-000330-36-IT进行中（未招募）不适用
Phase 3 Randomized Study of TLK286 versus Gefitinib(Iressa) as Third-Line Therapy in Locally Advanced orMetastatic Non-Small Cell Lung Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- TELIK, INC.
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNon Small Cell Lung CarcinomaNCT00080340Telik520
进行中（未招募）
不适用
A Clinical Trial to Compare the Effectiveness of TLK286 (Telcyta?) and Gefitinib (Iressa®) in Non-Small Cell Lung Canceron-small cell lung cancer, including squamous cell carcinoma, undifferentiated carcinoma, adenocarcinoma, mixed (adenocarcinoma with squamous cell carcinoma) or large cell carcinoma, recurrent or resistant following two prior chemotherapy regimens which must have included a platinum agent (carboplatin or cisplatin).MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-000330-36-ESTelik, Inc.530
进行中（未招募）
1 期
Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory or resistant ovarian cancer - ASSIST-5EUCTR2006-000366-36-GBTelik, Inc.244
进行中（未招募）
不适用
Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory or resistant ovarian cancer - ASSIST-5platinum refractory or resistant ovarian cancerMedDRA version: 8.1Level: LLTClassification code 10033160EUCTR2006-000366-36-BETelik, Inc.244
已完成
3 期
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian CancerOvarian NeoplasmsNCT00057720Telik440